[{"orgOrder":0,"company":"LFB Group","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ LFB Group","highestDevelopmentStatusID":"6","companyTruncated":"LFB Group \/ LFB Group"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Roledumab","moa":"Blood group Rh(D) polypeptide","graph1":"Hematology","graph2":"Phase II","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LFB-R603","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"LFB Group","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Antithrombin Alfa","moa":"Coagulation factor X | Thrombin","graph1":"Hematology","graph2":"Phase IV","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ LFB Group","highestDevelopmentStatusID":"11","companyTruncated":"LFB Group \/ LFB Group"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Coagulation Factor VIIa","moa":"F7a","graph1":"Genetic Disease","graph2":"Phase I","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"LFB Group","sponsor":"LFB Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Coagulation Factor VIIa, Recombinant","moa":"Factor VIIa","graph1":"Genetic Disease","graph2":"Phase III","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ LFB Group","highestDevelopmentStatusID":"10","companyTruncated":"LFB Group \/ LFB Group"},{"orgOrder":0,"company":"LFB Group","sponsor":"LFB USA","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Coagulation Factor VIIa, Recombinant","moa":"Factor VIIa","graph1":"Genetic Disease","graph2":"Phase III","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ LFB USA","highestDevelopmentStatusID":"10","companyTruncated":"LFB Group \/ LFB USA"},{"orgOrder":0,"company":"LFB Group","sponsor":"LFB USA","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Coagulation Factor VIIa, Recombinant","moa":"Factor VIIa","graph1":"Genetic Disease","graph2":"Phase III","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ LFB USA","highestDevelopmentStatusID":"10","companyTruncated":"LFB Group \/ LFB USA"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Coagulation Factor VIIa, Recombinant","moa":"Factor VIIa","graph1":"Genetic Disease","graph2":"Phase III","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"LFB Group","sponsor":"HEMA Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eptacog Alpha","moa":"Factor X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ HEMA Biologics","highestDevelopmentStatusID":"15","companyTruncated":"LFB Group \/ HEMA Biologics"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eptacog Beta","moa":"Thioredoxin reductase (PRDX5)","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eptacog Beta","moa":"Thioredoxin reductase (PRDX5)","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"LFB Group","sponsor":"LFB Group","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Eptacog Beta","moa":"Thioredoxin reductase (PRDX5)","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"LFB Group \/ LFB Group","highestDevelopmentStatusID":"8","companyTruncated":"LFB Group \/ LFB Group"},{"orgOrder":0,"company":"LFB Group","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"c\u03b1Stx1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ LFB Biotechnologies","highestDevelopmentStatusID":"8","companyTruncated":"LFB Group \/ LFB Biotechnologies"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Hemoleven","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Human Fibrinogen Concentrate","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Human Fibrinogen Concentrate","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"LFB Group","sponsor":"LFB Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ LFB Group","highestDevelopmentStatusID":"10","companyTruncated":"LFB Group \/ LFB Group"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Recombinant Human Antithrombin","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"LFB Group","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Human Antithrombin","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LFB Group \/ LFB Group","highestDevelopmentStatusID":"6","companyTruncated":"LFB Group \/ LFB Group"},{"orgOrder":0,"company":"LFB Group","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"I10E","moa":"Unknown","graph1":"Neurology","graph2":"Phase III","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ TFS Trial Form Support","highestDevelopmentStatusID":"10","companyTruncated":"LFB Group \/ TFS Trial Form Support"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"I10E","moa":"Unknown","graph1":"Neurology","graph2":"Phase III","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"I10E","moa":"Unknown","graph1":"Neurology","graph2":"Phase III","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"LFB Group","sponsor":"LFB Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ LFB Group","highestDevelopmentStatusID":"1","companyTruncated":"LFB Group \/ LFB Group"}]
Find Clinical Drug Pipeline Developments & Deals by LFB Group
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
